Akero Therapeutics, Inc. AKRO
We take great care to ensure that the data presented and summarized in this overview for Akero Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AKRO
View all-
Janus Henderson Group PLC London, X06.74MShares$324 Million0.19% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$275 Million10.64% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$268 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$263 Million4.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$218 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.51MShares$217 Million0.03% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.5MShares$168 Million3.41% of portfolio
-
Wellington Management Group LLP Boston, MA3.41MShares$164 Million0.03% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.04MShares$146 Million5.76% of portfolio
-
State Street Corp Boston, MA2.75MShares$132 Million0.01% of portfolio
Latest Institutional Activity in AKRO
Top Purchases
Top Sells
About AKRO
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Transactions at AKRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2025
|
Scott A. Gangloff Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,600
+8.98%
|
$49,400
$19.62 P/Share
|
|
Aug 12
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,500
-2.99%
|
$600,000
$48.02 P/Share
|
|
Aug 12
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+5.62%
|
$262,500
$21.1 P/Share
|
|
Aug 12
2025
|
Jane Henderson |
SELL
Open market or private sale
|
Direct |
3,000
-24.2%
|
$141,000
$47.46 P/Share
|
|
Aug 12
2025
|
Jane Henderson |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+19.48%
|
$21,000
$7.01 P/Share
|
|
Aug 11
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.95%
|
$1,440,000
$48.79 P/Share
|
|
Aug 05
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.54%
|
$612,500
$49.28 P/Share
|
|
Aug 05
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.51%
|
$262,500
$21.09 P/Share
|
|
Jul 16
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.99%
|
$530,000
$53.17 P/Share
|
|
Jul 16
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.97%
|
$190,000
$19.87 P/Share
|
|
Jul 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.76%
|
$1,530,000
$51.15 P/Share
|
|
Jul 07
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-2.34%
|
$637,500
$51.85 P/Share
|
|
Jul 07
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.51%
|
$262,500
$21.09 P/Share
|
|
Jul 01
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
2,000
-6.27%
|
$104,000
$52.88 P/Share
|
|
Jun 30
2025
|
Andrew Cheng President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
890
+0.16%
|
$20,470
$23.87 P/Share
|
|
Jun 30
2025
|
Scott A. Gangloff Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
299
+1.24%
|
$6,877
$23.87 P/Share
|
|
Jun 30
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
890
+0.53%
|
$20,470
$23.87 P/Share
|
|
Jun 30
2025
|
William Richard White Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
890
+1.5%
|
$20,470
$23.87 P/Share
|
|
Jun 30
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
193
+0.6%
|
$4,439
$23.87 P/Share
|
|
Jun 30
2025
|
Jonathan Young Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
890
+0.45%
|
$20,470
$23.87 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 304K shares |
|---|---|
| Exercise of conversion of derivative security | 953K shares |
| Open market or private purchase | 400K shares |
| Open market or private sale | 1.27M shares |
|---|---|
| Bona fide gift | 28.1K shares |